Efficacy evaluation of the C-strain-based vaccines against the subgenotype 2.1d classical swine fever virus emerging in China
作者单位：State Key Laboratory of Veterinary BiotechnologyHarbin Veterinary Research InstituteChinese Academy of Agricultural Sciences
会议名称：《中国畜牧兽医学会动物传染病学分会第九次全国会员代表大会暨第十七次全国学术研讨会》
会议日期：2017年
学科分类：090601[农学-基础兽医学] 09[农学] 0906[农学-兽医学]
关 键 词：Classical swine fever virus Subgenotype 2.1d C-strain vaccines Efficacy
摘 要：Classical swine fever(CSF) is a devastating infectious disease of pigs caused by classical swi ne fever virus(CSFV).The disease has been controlled following extensive vaccination with the 1 apinized attenuated vaccine C-strain for decades in ***,frequent CSF outbreaks occurr ed recently in a large number of C-strain-vaccinated pig farms in China and a new subgenotype 2.1 d of CSFV has been reported to be responsible for the *** we analyzed the molecul ar variations and antigenic differences among the C-strain-based commercial vaccines of different o rigins from different manufacturers in China,and reevaluated the vaccines against the emerging su bgenotype 2.1 d strain of *** results showed that the C-strain adapted to the continuous ST cell line(C) contain a unique M290 K variation on the E2 protein,compared to those of prima ry BT cells(C) or rabbit origin(C) and the traditional C-strain sequences available in the Ge nBank *** neutralization test revealed the antigenic differences between Cst and Cbt or ***,the neutralizing titers of porcine anti-C-strain sera against the CSFV isolate of su bgenotype 2.1 d were significantly lower than those against C-strain or Shimen *** C-strainvaccinated,subgenotype 2.1 d HLJZZ2014 strain-challenged pigs did not show any clinical signs an d all ***,these pigs displayed mild pathological and histological lesions,and the C SFV viral RNA was detected in the various tissue and blood *** together,the C-strain-based vaccines of different origins showed molecular variations and antigenic differences,and cou1 d provide clinical but not pathological and virological protection against the subgenotype 2.1 d CS FV emerging in *** investigation is needed to comprehensively assess the efficacy of C-strain of different doses against the subgenotype 2.1 d CSFV.